Dosar de subiect
Access to Merck's Keytruda Limited by Price and Patents Globally
Primul articol: 13 apr. 2026, 08:06
|
Ultima actualizare: 13 apr. 2026, 08:06
|
1 sursa
|
1 articol
Mai multe surse. Mai putina manipulare.
Analiza editoriala
Bazat pe 1 sursa, 1 articol
A joint investigation by Deutsche Welle and the ICIJ has uncovered significant barriers to accessing Merck's cancer drug, Keytruda, in many parts of the world. The investigation points to high prices and patent protections as key factors limiting availability, particularly in lower-income countries. This disparity raises ethical concerns about equitable access to lifesaving treatments.Articole despre acest subiect
Merck's Keytruda: A lifesaving drug, a global divide
A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of the world's best selling drugs while leaving many patients struggling to access it.
Citeste pe Deutsche Welle →